---
title: "COYA.US (COYA.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/COYA.US/news.md"
symbol: "COYA.US"
name: "COYA.US"
parent: "https://longbridge.com/zh-HK/quote/COYA.US.md"
datetime: "2026-03-14T22:54:52.846Z"
locales:
  - [en](https://longbridge.com/en/quote/COYA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/COYA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/COYA.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/COYA.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/COYA.US/news.md)


# COYA.US (COYA.US) — 相關新聞

### [Coya Therapeutics Hosts Webinar on ALS Drug Development and Clinical Progress](https://longbridge.com/zh-HK/news/275462293.md)
*2026-02-10T13:02:07.000Z*
### [HC Wainwright Analysts Raise Earnings Estimates for COYA](https://longbridge.com/zh-HK/news/274806627.md)
*2026-02-04T11:55:52.000Z*
> HC Wainwright analysts have raised their Q1 2026 earnings estimates for Coya Therapeutics (NASDAQ:COYA) from ($0.37) to 

### [Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/zh-HK/news/274486555.md)
*2026-02-02T08:47:17.000Z*
> Coya Therapeutics, Inc. (NASDAQ:COYA) has received a consensus recommendation of "Moderate Buy" from six analysts. One a

### [Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating](https://longbridge.com/zh-HK/news/271951956.md)
*2026-01-08T14:45:49.000Z*
> Ram Selvaraju from H.C. Wainwright maintains a Buy rating on Coya Therapeutics with a price target of $18.00. He cites e

### [Coya Therapeutics Reports Positive Results from FTD Study of Low-Dose IL-2 and CTLA4-Ig Combination Therapy](https://longbridge.com/zh-HK/news/271936162.md)
*2026-01-08T13:01:32.000Z*
### [Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages](https://longbridge.com/zh-HK/news/271885565.md)
*2026-01-08T06:25:47.000Z*
> Coya Therapeutics, Inc. (NASDAQ:COYA) has received a consensus rating of "Moderate Buy" from six brokerages. One analyst

### [FDA Accepts IND Application for Coya Therapeutics’ COYA 302 for Frontotemporal Dementia](https://longbridge.com/zh-HK/news/271516818.md)
*2026-01-05T13:01:45.000Z*
### [Coya Therapeutics Secures Health Canada Approval to Begin ALS Trial](https://longbridge.com/zh-HK/news/270617236.md)
*2025-12-23T13:00:58.000Z*